{"filing":{"accession_number":"0001493152-26-042483","cik":"0001971532","ticker":"TELO","company_name":"Telomir Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226042483/form8-k.htm"},"events":[{"id":33137,"run_id":30462,"accession_number":"0001493152-26-042483","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Telomir disclosed preclinical research findings from The Ohio State University demonstrating that Telomir-Zn inhibits cell growth in human and canine osteosarcoma models, and announced a strategic dual-pathway development approach: advancing its lead TNBC program toward Phase 1/2 enrollment while assessing a potential in vivo efficacy study in canine osteosarcoma. This is a material operational/strategic disclosure of research progress and development pathway expansion for a clinical-stage biotech company, but does not fit the specific categories of earnings release, M\u0026A, litigation, or other named event types.","company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":36498,"accession_number":"0001493152-26-042483","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Telomir disclosed preclinical research findings from The Ohio State University demonstrating that Telomir-Zn inhibits cell growth in human and canine osteosarcoma models, and announced a strategic dual-pathway development approach: advancing its lead TNBC program toward Phase 1/2 enrollment while assessing a potential in vivo efficacy study in canine osteosarcoma. This is a material operational/strategic disclosure of research progress and development pathway expansion for a clinical-stage biotech company, but does not fit the specific categories of earnings release, M\u0026A, litigation, or other named event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T12:02:53.787647+00:00","company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","filing_date":"2026-09-14"}]}